Emily C. Somers

ORCID: 0000-0001-5234-3978 · 3 papers in corpus
review 2012
Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility
Clinical medicine insights. Reproductive health ·doi:10.4137/cmrh.s10415

Women with autoimmune diseases such as lupus, scleroderma, and vasculitis receiving cyclophosphamide for severe disease manifestations risk primary ovarian insufficiency(POI) due to gonadotoxicity of this therapy. In addition to loss of rep…

review 2009
Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases
Journal of autoimmunity ·doi:10.1016/j.jaut.2009.09.008

Previous studies have estimated a prevalence of a broad grouping of autoimmune diseases of 3.2%, based on literature review of studies published between 1965 and 1995, and 5.3%, based on national hospitalization registry data in Denmark. We…

nonrandomized-trial 2005
Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus
Arthritis and rheumatism ·doi:10.1002/art.21263

OBJECTIVE: Cyclophosphamide (CYC) therapy for systemic lupus erythematosus (SLE), a disease predominantly affecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ovarian failure (POF). This study…